Literature DB >> 16424736

Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.

J Carlet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16424736     DOI： 10.1097/01.ccm.0000198329.85851.8e

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  14 in total

1.  Incidence of sepsis in hospitalized patients.

Authors:  Rui Moreno; Susana Afonso; Teresa Fevereiro
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

2.  Time course of organ failure in patients with septic shock treated with hydrocortisone: results of the Corticus study.

Authors:  R Moreno; C L Sprung; D Annane; S Chevret; J Briegel; D Keh; M Singer; Y G Weiss; D Payen; B H Cuthbertson; J-L Vincent
Journal:  Intensive Care Med       Date:  2011-08-17       Impact factor: 17.440

3.  Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.

Authors:  Guido Bertolini; Carlotta Rossi; Abramo Anghileri; Sergio Livigni; Antonio Addis; Daniele Poole
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

4.  Sepsis mortality prediction based on predisposition, infection and response.

Authors:  Rui P Moreno; Barbara Metnitz; Leopold Adler; Anette Hoechtl; Peter Bauer; Philipp G H Metnitz
Journal:  Intensive Care Med       Date:  2007-12-04       Impact factor: 17.440

5.  Organ failure in sepsis.

Authors:  Herwig Gerlach; Susanne Toussaint
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

6.  Reversal of refractory septic shock with drotrecogin alpha (activated).

Authors:  A Vieillard-Baron; V Caille; C Charron; G Belliard; P Aegerter; B Page; F Jardin
Journal:  Intensive Care Med       Date:  2009-06-16       Impact factor: 17.440

7.  Activated protein C in septic shock: a propensity-matched analysis.

Authors:  Farid Sadaka; Jacklyn O'Brien; Matthew Migneron; Julie Stortz; Alexander Vanston; Robert W Taylor
Journal:  Crit Care       Date:  2011-03-08       Impact factor: 9.097

8.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15

9.  Bai-hu-tang, ancient chinese medicine formula, may provide a new complementary treatment option for sepsis.

Authors:  Chien-Jung Lin; Yi-Chang Su; Cheng-Hung Lee; Tsai-Chung Li; Yun-An Chen; Sunny Jui-Shan Lin
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-15       Impact factor: 2.629

Review 10.  Clinical trials in severe sepsis with drotrecogin alfa (activated).

Authors:  Pierre-François Laterre
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.